Date published: 2025-10-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

SLC38A9 Activators

SLC38A9, a member of the solute carrier family, is a protein that is intricately involved in amino acid transport and mTOR signaling. The activity of this protein can be influenced by several chemical activators through various signaling pathways. Compounds that elevate intracellular levels of cyclic adenosine monophosphate (cAMP) can enhance the functional activity of SLC38A9. This elevation can be achieved through direct stimulation of adenylyl cyclase or by inhibiting the degradation of cAMP via phosphodiesterase inhibition. Increased cAMP levels result in a cascade of events that may lead to the activation of protein kinase A (PKA) and subsequent phosphorylation of downstream targets, which could include pathways that indirectly influence SLC38A9 activity. Additionally, certain phosphodiesterase inhibitors specifically elevate cyclic guanosine monophosphate (cGMP) levels, which can also modulate pathways that intersect with cAMP signaling, indirectly supporting the activation of SLC38A9.

Beyond the cAMP/cGMP axis, other molecular entities function through distinct mechanisms to activate SLC38A9. Compounds that inhibit tyrosine kinases or phosphoinositide 3-kinases (PI3K) can alter downstream signaling pathways, potentially leading to the activation of SLC38A9. For example, by modulating the AKT pathway, a PI3K inhibitor may indirectly activate SLC38A9 as part of the cellular response to changes in nutrient availability or growth signals. Similarly, inhibitors of protein kinase C may alter cellular signaling in a manner that promotes SLC38A9 activity. Furthermore, certain polyphenols activate sirtuin pathways, which are known to influence the mammalian target of rapamycin (mTOR) signaling, a key regulator of amino acid sensing and transport.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Forskolin

66575-29-9sc-3562
sc-3562A
sc-3562B
sc-3562C
sc-3562D
5 mg
50 mg
1 g
2 g
5 g
$76.00
$150.00
$725.00
$1385.00
$2050.00
73
(3)

Directly stimulates adenylyl cyclase, increasing intracellular cAMP levels, thereby potentially enhancing SLC38A9 activity.

IBMX

28822-58-4sc-201188
sc-201188B
sc-201188A
200 mg
500 mg
1 g
$159.00
$315.00
$598.00
34
(1)

Non-selective phosphodiesterase inhibitor, prevents cAMP degradation, potentially supporting SLC38A9 function.

Rolipram

61413-54-5sc-3563
sc-3563A
5 mg
50 mg
$75.00
$212.00
18
(1)

Selective inhibitor of phosphodiesterase 4, increasing cAMP concentrations, which may enhance SLC38A9 activity.

Isoproterenol Hydrochloride

51-30-9sc-202188
sc-202188A
100 mg
500 mg
$27.00
$37.00
5
(0)

β-adrenergic agonist that increases cAMP levels, possibly facilitating SLC38A9 activity.

Zaprinast (M&B 22948)

37762-06-4sc-201206
sc-201206A
25 mg
100 mg
$103.00
$245.00
8
(2)

Inhibits phosphodiesterase 5, increasing cGMP levels, which can indirectly affect cAMP pathways, aiding SLC38A9 activity.

Vinpocetine

42971-09-5sc-201204
sc-201204A
sc-201204B
20 mg
100 mg
15 g
$55.00
$214.00
$2400.00
4
(1)

Inhibits phosphodiesterase 1, elevating cAMP and cGMP levels, potentially contributing to SLC38A9 activation.

Cilostamide (OPC 3689)

68550-75-4sc-201180
sc-201180A
5 mg
25 mg
$90.00
$350.00
16
(1)

Phosphodiesterase 3 inhibitor, increasing cAMP levels, which could enhance SLC38A9 functional activity.

Luteolin

491-70-3sc-203119
sc-203119A
sc-203119B
sc-203119C
sc-203119D
5 mg
50 mg
500 mg
5 g
500 g
$26.00
$50.00
$99.00
$150.00
$1887.00
40
(1)

Known to inhibit protein kinase C, which may lead to alterations in signaling pathways that activate SLC38A9.

Genistein

446-72-0sc-3515
sc-3515A
sc-3515B
sc-3515C
sc-3515D
sc-3515E
sc-3515F
100 mg
500 mg
1 g
5 g
10 g
25 g
100 g
$26.00
$92.00
$120.00
$310.00
$500.00
$908.00
$1821.00
46
(1)

Tyrosine kinase inhibitor, can alter downstream signaling, potentially promoting SLC38A9 activity.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

PI3K inhibitor, modulates downstream AKT pathway, which may result in the functional activation of SLC38A9.